These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11472263

  • 1. Physiochemical aspects of tubulin-interacting antimitotic drugs.
    Correia JJ, Lobert S.
    Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
    [Abstract] [Full Text] [Related]

  • 2. Effects of antimitotic agents on tubulin-nucleotide interactions.
    Correia JJ.
    Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
    [Abstract] [Full Text] [Related]

  • 3. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.
    Wilson L, Panda D, Jordan MA.
    Cell Struct Funct; 1999 Oct; 24(5):329-35. PubMed ID: 15216890
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
    Smith CD, Zhang X.
    J Biol Chem; 1996 Mar 15; 271(11):6192-8. PubMed ID: 8626409
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA.
    Curr Med Chem Anticancer Agents; 2002 Jan 15; 2(1):1-17. PubMed ID: 12678749
    [Abstract] [Full Text] [Related]

  • 6. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH.
    FEBS Lett; 1995 Dec 11; 377(1):59-61. PubMed ID: 8543019
    [Abstract] [Full Text] [Related]

  • 7. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S, Bhattacharyya B.
    Mol Cell Biochem; 2003 Nov 11; 253(1-2):41-7. PubMed ID: 14619954
    [Abstract] [Full Text] [Related]

  • 8. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism.
    Derry WB, Wilson L, Jordan MA.
    Cancer Res; 1998 Mar 15; 58(6):1177-84. PubMed ID: 9515803
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
    Shi Q, Chen K, Morris-Natschke SL, Lee KH.
    Curr Pharm Des; 1998 Jun 15; 4(3):219-48. PubMed ID: 10197041
    [Abstract] [Full Text] [Related]

  • 16. Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop.
    Abel AC, Mühlethaler T, Dessin C, Schachtsiek T, Sammet B, Sharpe T, Steinmetz MO, Sewald N, Prota AE.
    J Biol Chem; 2024 Jun 15; 300(6):107363. PubMed ID: 38735475
    [Abstract] [Full Text] [Related]

  • 17. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL, Pettit GR, Hamel E.
    J Biol Chem; 1990 Oct 05; 265(28):17141-9. PubMed ID: 2211617
    [Abstract] [Full Text] [Related]

  • 18. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics.
    Downing KH.
    Annu Rev Cell Dev Biol; 2000 Oct 05; 16():89-111. PubMed ID: 11031231
    [Abstract] [Full Text] [Related]

  • 19. Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin.
    Sáez-Calvo G, Sharma A, Balaguer FA, Barasoain I, Rodríguez-Salarichs J, Olieric N, Muñoz-Hernández H, Berbís MÁ, Wendeborn S, Peñalva MA, Matesanz R, Canales Á, Prota AE, Jímenez-Barbero J, Andreu JM, Lamberth C, Steinmetz MO, Díaz JF.
    Cell Chem Biol; 2017 Jun 22; 24(6):737-750.e6. PubMed ID: 28579361
    [Abstract] [Full Text] [Related]

  • 20. High-resolution microtubule structures reveal the structural transitions in αβ-tubulin upon GTP hydrolysis.
    Alushin GM, Lander GC, Kellogg EH, Zhang R, Baker D, Nogales E.
    Cell; 2014 May 22; 157(5):1117-29. PubMed ID: 24855948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.